Nurix Therapeutics (NRIX) Net Cash Flow (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Net Cash Flow for 8 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Cash Flow fell 142.07% year-over-year to -$3.5 million; the TTM figure through May 2026 stood at -$16.5 million (up 49.25% YoY), while the FY2025 annual figure was $137.0 million, up 147.48% from the prior year.
• Net Cash Flow improved to -$3.5 million in Q2 2026 per NRIX's latest filing, from -$175.8 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $168.5 million in Q4 2025 and bottomed at -$175.8 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$674388.9 across 5 years, with a median of -$2.3 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 2681.55% — and 2025, when it soared 1438.59%.
• Nurix Therapeutics' Net Cash Flow stood at $16.9 million in 2022, then dropped by 27.16% to $12.3 million in 2023, then decreased by 11.12% to $11.0 million in 2024, then jumped by 1438.59% to $168.5 million in 2025, then sank by 102.08% to -$3.5 million in 2026.
• Business Quant data shows NRIX's Net Cash Flow at -$3.5 million in Q2 2026, -$175.8 million in Q1 2026, and $168.5 million in Q4 2025.